Medtronic plc (NYSE:MDT) entered fiscal 2027 expecting solid growth. One quarter later, strong demand for its cardiovascular devices has given management enough confidence to raise that outlook.
The company increased its organic revenue growth forecast and lifted the lower end of its adjusted earnings range after beating quarterly expectations. Its cardiovascular business was the standout, helped by rapid growth in pulsed field ablation products used to treat irregular heart rhythms. Medtronic (NYSE:MDT) is also investing in heart-valve technology and surgical robotics to strengthen its longer-term growth portfolio.
Bull Case
Medtronic now expects fiscal 2027 organic revenue growth of between 7.25% and 7.75%, up from its previous forecast of 6.75% to 7.25%. The midpoint consequently increased from 7% to 7.5%, representing a meaningful improvement in management’s expectations. The company also raised the lower end of its adjusted earnings forecast to $5.94 per share from $5.90 while maintaining the upper end at $6. Although the profit revision is smaller, it narrows the range toward the higher end of the original outlook.
Quarterly performance helps explain the increased confidence. Medtronic reported adjusted earnings of $1.45 per share on revenue of $9.76 billion. Analysts surveyed by LSEG had expected earnings of $1.39 per share and sales of $9.55 billion. One of the strongest drivers of momentum came from cardiovascular devices, with sales in the cardiovascular segment increasing 19.5% to $3.93 billion. The company’s pulsed field ablation portfolio, which treats irregular heart rhythms, grew 88% and was a major contributor to the segment’s performance.
CEO Geoff Martha said Medtronic’s confidence reflects not only the quarter’s strength but also the breadth of performance across its businesses and the growing contribution from newer platforms, which suggests the company’s outlook is not based entirely on one established product category.
Medtronic is also deploying capital into additional growth markets. It agreed to invest $80 million in heart-valve repair device company Pi-Cardia and received an option to acquire it for $210 million. In a separate development, Medtronic invested $700 million in Cornerstone Robotics and obtained rights to distribute the Sentire robotic surgical system in certain markets outside the United States. Martha told Reuters that soft-tissue robotic surgery penetration in emerging markets remains below 1%, describing Sentire as complementary to Medtronic’s Hugo system, giving the company another way to pursue an underpenetrated market.
Bear Case
The earnings guidance increase is relatively modest. Medtronic raised only the lower end by four cents while leaving the $6 upper limit unchanged. The revision signals greater confidence but does not represent a substantial increase in expected profitability. The company’s cardiovascular results also create a demanding comparison for future quarters. An 88% increase in pulsed field ablation and 19.5% cardiovascular growth may be difficult to sustain as the business becomes larger. Medtronic has not said those specific growth rates will continue.
Tariffs remain another uncertainty. Chief Financial Officer Thierry Pieton said refunds received during the quarter almost covered the duties Medtronic paid. However, the company has not included future refunds in its outlook, meaning later tariff costs may not receive the same offset.
The strategic investments carry execution risk as well. Medtronic must demonstrate that its $700 million Cornerstone investment and international distribution rights can translate low robotic-surgery penetration into meaningful sales. Likewise, the Pi-Cardia investment and acquisition option do not guarantee regulatory progress or commercial adoption for its technology. Finally, management’s emphasis on acquisitions in higher-growth medtech categories requires careful capital allocation. Large potential patient pools can support attractive opportunities, but investments generate value only if Medtronic integrates or commercializes the underlying technologies successfully.
Conclusion
Medtronic’s raised organic-growth outlook, earnings beat, and accelerating cardiovascular portfolio provide credible evidence that its newer platforms are contributing more meaningfully. Pulsed field ablation is currently the clearest growth driver, while the Pi-Cardia and Cornerstone investments could broaden the opportunity.
The key question for the company is durability, as Medtronic must sustain momentum after exceptionally strong cardiovascular growth, manage tariff uncertainty, and convert its latest investments into commercial results. For now, the higher guidance strengthens the growth thesis, but execution will determine whether this quarter marks a lasting acceleration.
READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth?
This article is originally published at Insider Monkey.
